Comparative Pharmacology
Head-to-head clinical analysis: GANTANOL DS versus SULFAMETHOXAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANTANOL DS versus SULFAMETHOXAZOLE.
GANTANOL-DS vs SULFAMETHOXAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfamethoxazole is a sulfonamide that inhibits bacterial dihydrofolate synthesis by competing with para-aminobenzoic acid, thereby blocking folate synthesis. Trimethoprim inhibits bacterial dihydrofolate reductase, converting dihydrofolate to tetrahydrofolate. This sequential blockade produces bactericidal activity.
Displaces dihydropteroate synthetase from its substrate para-aminobenzoic acid (PABA), inhibiting bacterial folate synthesis. Bacteriostatic against susceptible organisms.
2 g (DS strength: 2 g sulfamethoxazole/400 mg trimethoprim) orally every 12 hours for 14-21 days for Pneumocystis jirovecii pneumonia.
800 mg sulfamethoxazole with 160 mg trimethoprim (DS tablet) orally every 12 hours.
None Documented
None Documented
Clinical Note
moderateSulfamethoxazole + Gatifloxacin
"Sulfamethoxazole may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSulfamethoxazole + Rosoxacin
"Sulfamethoxazole may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateSulfamethoxazole + Trovafloxacin
"Sulfamethoxazole may increase the hypoglycemic activities of Trovafloxacin."
Clinical Note
moderateSulfamethoxazole + Nalidixic acid
10-12 hours (sulfamethoxazole component); prolonged in renal impairment (up to 30 hours with CrCl <15 mL/min).
9-11 hours in adults with normal renal function. Prolonged in renal impairment: up to 20-30 hours. In neonates, 6-12 hours.
Primarily renal (70-100%) as unchanged drug and inactive metabolites (sulfamethoxazole N4-acetyl and glucuronide conjugates); <5% biliary/fecal.
Primarily renal; ~80-90% excreted unchanged in urine, with 15-30% as acetylated metabolite. Biliary/fecal <5%.
Category C
Category D/X
Sulfonamide Antibiotic
Sulfonamide Antibiotic
"Sulfamethoxazole may increase the hypoglycemic activities of Nalidixic acid."